Literature DB >> 23743589

The ideal crystalloid - what is 'balanced'?

Thomas J Morgan1.   

Abstract

PURPOSE OF REVIEW: This review explores the contemporary definition of the term 'balanced crystalloid' and outlines optimal design features and their underlying rationale. RECENT
FINDINGS: Crystalloid interstitial expansion is unavoidable, but also occurs with colloids when there is endothelial glycocalyx dysfunction. Reduced chloride exposure may lessen kidney dysfunction and injury with a possible mortality benefit. Exact balance from an acid-base perspective is achieved with a crystalloid strong ion difference of 24 mEq/l. This can be done simply by replacing 24 mEq/l of chloride in 0.9% sodium chloride with bicarbonate or organic anion bicarbonate substitutes. Potassium, calcium and magnesium additives are probably unnecessary. Large volumes of mildly hypotonic crystalloids such as lactated Ringer's solution reduce extracellular tonicity in volunteers and increase intracranial pressure in nonbrain-injured experimental animals. A total cation concentration of 154 mmol/l with accompanying anions provides isotonicity. Of the commercial crystalloids, Ringer's acetate solution is close to balanced from both acid-base and tonicity perspectives, and there is little current evidence of acetate toxicity in the context of volume loading, in contrast to renal replacement.
SUMMARY: The case for balanced crystalloids is growing but unproven. A large randomized controlled trial of balanced crystalloids versus 0.9% sodium chloride is the next step.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743589     DOI: 10.1097/MCC.0b013e3283632d46

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  16 in total

Review 1.  Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis.

Authors:  B Rochwerg; W Alhazzani; A Gibson; C M Ribic; A Sindi; D Heels-Ansdell; L Thabane; A Fox-Robichaud; L Mbuagbaw; W Szczeklik; F Alshamsi; S Altayyar; W Ip; G Li; M Wang; A Włudarczyk; Q Zhou; D Annane; D J Cook; R Jaeschke; G H Guyatt
Journal:  Intensive Care Med       Date:  2015-04-23       Impact factor: 17.440

Review 2.  Contemporary Approaches to Perioperative IV Fluid Therapy.

Authors:  Paul S Myles; Sam Andrews; Jonathan Nicholson; Dileep N Lobo; Monty Mythen
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

Review 3.  Crystalloid fluid choice in the critically ill : Current knowledge and critical appraisal.

Authors:  Carmen A Pfortmueller; Barbara Kabon; Joerg C Schefold; Edith Fleischmann
Journal:  Wien Klin Wochenschr       Date:  2018-03-02       Impact factor: 1.704

Review 4.  Septic Shock: Advances in Diagnosis and Treatment.

Authors:  Christopher W Seymour; Matthew R Rosengart
Journal:  JAMA       Date:  2015-08-18       Impact factor: 56.272

5.  Key Controversies in Colloid and Crystalloid Fluid Utilization.

Authors:  Erin N Frazee; David D Leedahl; Kianoush B Kashani
Journal:  Hosp Pharm       Date:  2015-06

Review 6.  Choice of Fluid Therapy in the Initial Management of Sepsis, Severe Sepsis, and Septic Shock.

Authors:  Ronald Chang; John B Holcomb
Journal:  Shock       Date:  2016-07       Impact factor: 3.454

Review 7.  Balanced Crystalloid Solutions.

Authors:  Matthew W Semler; John A Kellum
Journal:  Am J Respir Crit Care Med       Date:  2019-04-15       Impact factor: 21.405

Review 8.  Fluid therapy for septic shock resuscitation: which fluid should be used?

Authors:  Thiago Domingos Corrêa; Leonardo Lima Rocha; Camila Menezes Souza Pessoa; Eliézer Silva; Murillo Santucci Cesar de Assuncao
Journal:  Einstein (Sao Paulo)       Date:  2015-08-21

9.  Plasma-Lyte 148: A clinical review.

Authors:  Laurence Weinberg; Neil Collins; Kiara Van Mourik; Chong Tan; Rinaldo Bellomo
Journal:  World J Crit Care Med       Date:  2016-11-04

Review 10.  Effect of Intravenously Administered Crystalloid Solutions on Acid-Base Balance in Domestic Animals.

Authors:  W Muir
Journal:  J Vet Intern Med       Date:  2017-08-20       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.